Revvity Analyst Ratings
Revvity Analyst Ratings
Barclays Trims Price Target on Revvity to $115 From $116
Revvity Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), DocGo (DCGO) and Revvity (RVTY)
Bernstein Adjusts Price Target on Revvity to $123 From $125, Keeps Outperform Rating
Revvity (RVTY) Receives a Hold From Barclays
Nephron Adjusts Revvity's Price Target to $124 From $120
Barclays Keeps Their Hold Rating on Revvity (RVTY)
Raymond James Maintains Outperform on Revvity, Raises Price Target to $127
Revvity Analyst Ratings
Analysts Conflicted on These Healthcare Names: Exelixis (EXEL), Revvity (RVTY) and Becton Dickinson (BDX)
Revvity: A Cautious Hold Amidst Conservative Guidance and Operational Challenges
Buy Rating Affirmed: Revvity's Promising Turnaround and Prudent 2024 Outlook
Revvity: Hold Rating Affirmed Amidst Mixed Financial Performance and Cautious Outlook
BofA Securities Raises Price Target on Revvity to $117 From $104, Maintains Neutral Rating
The Latest Analyst Ratings For Revvity
Revvity Analyst Ratings
Revvity Analyst Ratings
UBS Downgrades Revvity to Neutral From Buy, Raises Price Target to $125 From $105